AACT.U VS CALA Stock Comparison

PerformanceVolatilityForecastSentimentTechnicalsEarningsProfitDividend
PerformanceVolatilityForecastSentimentTechnicalsEarningsProfitDividend

Performance

AACT.U
10/100

AACT.U returned 5.56% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

CALA
10/100

CALA returned -96.80% in the last 12 months. Based on the other stocks in it's sector with an average return of -9.81%, it's performance is below average giving it a grade of 10 of 100.

Volatility

AACT.U
83/100

AACT.U has had a higher than average amount of volatility over the last 12 months giving it a score of 83 of 100.

CALA
52/100

CALA has had a higher than average amount of volatility over the last 12 months giving it a grade of 52 of 100.

Forecast

AACT.U

"Forecast" not found for AACT.U

CALA
81/100

4 analysts offer 12-month price forecasts for CALA. Together, they have an average target of 2, the most optimistic forecast put CALA at 2 within 12-months and the most pessimistic has CALA at 2.

Sentiment

AACT.U

"Sentiment" not found for AACT.U

CALA
10/100

CALA does not have any recent conclusive social sentiment.

Technicals

AACT.U

"Technicals" not found for AACT.U

CALA
11/100

CALA receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

AACT.U

"Earnings" not found for AACT.U

CALA
10/100

CALA has missed earnings 9 times in the last 20 quarters.

Profit

AACT.U

"Profit" not found for AACT.U

CALA
10/100

Out of the last 20 quarters, CALA has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Dividend

AACT.U

"Dividend" not found for AACT.U

CALA
10/100

CALA has not paid a dividend in the last 5 years.

All score calculations are broken down here to help you make more informed investing decisions

Ares Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant Summary

New York Stock Exchange / AACT.U

Calithera Biosciences, Inc Summary

Nasdaq / CALA